170282-53-8

Basic information

• Product Name: Benzamide, 3-iodo-N-methoxy-N-methyl-
• CAS NO: 170282-53-8
• Molecular Formula: C9H10INO2
• Molecular Weight: 291.088
• Mol File: 170282-53-8.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Benzamide, 3-iodo-N-methoxy-N-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, 3-iodo-N-methoxy-N-methyl-(170282-53-8)
• EPA Substance Registry System: Benzamide, 3-iodo-N-methoxy-N-methyl-(170282-53-8)

Safety Data

• Hazardous Substances Data: 170282-53-8(Hazardous Substances Data)

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 618-51-9 3-Iodobenzoic acid 
• 1711-10-0 3-iodobenzoyl chloride 
• 1117-97-1 N,0-dimethylhydroxylamine 

Downstream Products

• 406162-36-5 [4-(3-chlorophenyl)-2-methoxy-6-quinolinyl](3-iodophenyl)-methanone 
• 717900-62-4 (4-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-(3-iodo-phenyl)-methanone 
• 1602731-56-5 C₂₂H₂₅N₅O 
• 1602732-13-7 C₂₂H₁₉N₅O₃S 
• 1602732-15-9 C₂₅H₂₂N₆O 
• 1602732-17-1 C₂₁H₂₀N₆OS 
• 1602732-20-6 C₂₁H₁₇N₅O 
• 1602732-22-8 C₂₂H₁₉N₅O₂ 
• 1602732-24-0 C₂₂H₁₉N₅O 
• 1602732-27-3 C₂₁H₁₆FN₅O 
• 1602732-29-5 C₂₁H₁₆BrN₅O 
• 1602732-31-9 C₂₁H₁₆IN₅O 
• 1602732-33-1 C₂₁H₁₈N₆O 
• 1602732-35-3 C₂₁H₁₆N₆O₃ 

Relevant articles and documents

Development of a p38α-selective radioactive probe for qualitative diagnosis of cancer using SPECT

Objective: p38 mitogen-activated protein (MAP) kinase (p38α) has drawn attention as a new target molecule for the treatment and diagnosis of cancer, and its overexpression and activation have been reported in various types of cancer. In this study, a single photon emission computed tomography (SPECT) imaging probe of p38α was developed to noninvasively image p38α activity for effective qualitative diagnosis of cancer. Methods: Pyrrolepyridine derivatives, m-YTM and p-YTM, were designed and synthesized based on the structure of the p38α-selective inhibitor. Radioactive iodine-labeled m-YTM, [125I]m-YTM, was synthesized because m-YTM greatly inhibited the phosphorylation of p38α upon examining the inhibitory effects of the compounds. After investigating the binding affinity of [125I]m-YTM to the recombinant p38α, a saturation binding experiment using activated p38α and inactive p38α was performed to determine the binding site. Uptake of [125I]m-YTM into various cancer cell lines was investigated, and the pharmacokinetics was evaluated using tumor-bearing mice. Results: The inhibitory activity of m-YTM was approximately 13 times higher than that of SB203580, a p38α-selective inhibitor. The binding site of [125I]m-YTM was estimated to be the p38α activating site, similar to that of SB203580, because the [125I]m-YTM bound strongly to both activated p38α and inactive p38α. Various different cancer cells incorporated [125I]m-YTM; however, its accumulation was significantly reduced by treatment with SB203580. Pharmacokinetics study of [125I]m-YTM in B-16 tumor-bearing mice was examined which revealed high accumulation of radioactivity in tumor tissues. The ratios of radioactivity in the B-16 tumor to that in blood were 3.1 and 50 after 1 and 24?h, respectively. The ratio of radioactivity in the tumor to that in blood in the tumor-bearing mice generated using other cancer cell lines was also ≥ 1 at 1?h after the administration of the probe. Conclusions: This study suggests that [123I]m-YTM has potential as a p38α imaging probe effective for various cancer types.

Identification of novel SIRT2-selective inhibitors using a click chemistry approach

A series of 114 SIRT inhibitor candidates was assembled using 'click chemistry', by reacting two alkynes bearing 2-anilinobenzamide pharmacophore with 57 azide building blocks in the presence of Cu(I) catalyst. Screening identified two SIRT2-selective inhibitors, which were more SIRT2-selective than AGK2, a known SIRT2 inhibitor. These findings will be useful for further development of SIRT2-selective inhibitors.

NOVEL IMIDAZOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS

Compounds of the general formula (I) are valuable therapeutics for the treatment of cancer and cancer related diseases.